[1]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[2]
Hwang, J.Y.; Lee, H.J.; Go, M.J.; Jang, H.B.; Choi, N.H.; Bae, J.B.; Castillo-Fernandez, J.E.; Bell, J.T.; Spector, T.D.; Lee, H.J.; Kim, B.J. Genome-wide methylation analysis identifies ELOVL5 as an epigenetic biomarker for the risk of type 2 diabetes mellitus. Sci. Rep., 2018, 8(1), 14862.
[http://dx.doi.org/10.1038/s41598-018-33238-9] [PMID: 30291282]
[http://dx.doi.org/10.1038/s41598-018-33238-9] [PMID: 30291282]
[3]
Cirillo, E.; Kutmon, M.; Gonzalez Hernandez, M.; Hooimeijer, T.; Adriaens, M.E.; Eijssen, L.M.T.; Parnell, L.D.; Coort, S.L.; Evelo, C.T. From SNPs to pathways: Biological interpretation of type 2 diabetes (T2DM) genome wide association study (GWAS) results. PLoS One, 2018, 13(4)e0193515
[http://dx.doi.org/10.1371/journal.pone.0193515] [PMID: 29617380]
[http://dx.doi.org/10.1371/journal.pone.0193515] [PMID: 29617380]
[4]
Liu, Y.; Zhao, J.; Jiang, T.; Yu, M.; Jiang, G.; Hu, Y. A pathway analysis of genome-wide association study highlights novel type 2 diabetes risk pathways. Sci. Rep., 2017, 7(1), 12546.
[http://dx.doi.org/10.1038/s41598-017-12873-8] [PMID: 28970525]
[http://dx.doi.org/10.1038/s41598-017-12873-8] [PMID: 28970525]
[5]
Barseem, N.F.; El Ella, S.S.A.; Tawfik, M.A.; El-Nehrawy, R.R. The Potential implication of FTO rs17817449 gene polymorphism on bmi mediated risk for type2 diabetes among obese Egyptian children and adolescents. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(5), 697-704.
[http://dx.doi.org/10.2174/1871530319666190101124751] [PMID: 30621571]
[http://dx.doi.org/10.2174/1871530319666190101124751] [PMID: 30621571]
[6]
Rabiee, M.; Marjani, A.; Khajeniazi, S.; Mojerloo, M. Genetic polymorphisms of cytochrome p450 (2c9) enzyme in patients with type 2 diabetes mellitus in Turkmen and fars ethnic groups. Endocr. Metab. Immune Disord. Drug Targets, 2018, 18(6), 653-661.
[http://dx.doi.org/10.2174/1871530318666180821122853] [PMID: 30129421]
[http://dx.doi.org/10.2174/1871530318666180821122853] [PMID: 30129421]
[7]
Stols-Gonçalves, D.; Tristão, L.S.; Henneman, P.; Nieuwdorp, M. Epigenetic markers and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease. Curr. Diab. Rep., 2019, 19(6), 31.
[http://dx.doi.org/10.1007/s11892-019-1151-4] [PMID: 31044315]
[http://dx.doi.org/10.1007/s11892-019-1151-4] [PMID: 31044315]
[8]
Sommese, L.; Benincasa, G.; Lanza, M.; Sorriento, A.; Schiano, C.; Lucchese, R.; Alfano, R.; Nicoletti, G.F.; Napoli, C. Novel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes. J. Diabetes Complications, 2018, 32(11), 1076-1084.
[http://dx.doi.org/10.1016/j.jdiacomp.2018.08.012] [PMID: 30190170]
[http://dx.doi.org/10.1016/j.jdiacomp.2018.08.012] [PMID: 30190170]
[9]
Ahmed, S.M.; Johar, D.; Ali, M.M.; El-Badri, N. Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 742-750.
[http://dx.doi.org/10.2174/1871530319666190305131813] [PMID: 30834843]
[http://dx.doi.org/10.2174/1871530319666190305131813] [PMID: 30834843]
[10]
Johar, D.; Ahmed, S.M.; El Hayek, S.; Al-Dewik, N.; Bahbah, E.I.; Omar, N.H.; Mustafa, M.; Salman, D.O.; Fahmey, A.; Mottawea, M.; Azouz, R.A.M.; Bernstein, L. Diabetes-Induced Proteome Changes Throughout Development. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 730-741.
[PMID: 31038056]
[PMID: 31038056]
[11]
Tiwari, P.; Katyal, A.; Khan, M.F.; Ashraf, G.M.; Ahmad, K. Lead Optimization Resources in Drug Discovery for Diabetes. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 751-770.
[http://dx.doi.org/10.2174/1871530319666190304121826] [PMID: 30834844]
[http://dx.doi.org/10.2174/1871530319666190304121826] [PMID: 30834844]
[12]
Hossan, T.; Kundu, S.; Alam, S.S.; Nagarajan, S. Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 771-781.
[http://dx.doi.org/10.2174/1871530319666190301145545] [PMID: 30827271]
[http://dx.doi.org/10.2174/1871530319666190301145545] [PMID: 30827271]
[13]
Khatami, F.; Mohajeri-Tehrani, M.R.; Tavangar, S.M. The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(6), 719-729.
[http://dx.doi.org/10.2174/1871530319666190228102212] [PMID: 31122183]
[http://dx.doi.org/10.2174/1871530319666190228102212] [PMID: 31122183]
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
Textbook of Advanced Dermatology: Pearls for Academia and Skin Clinics (Part 1)
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Software and Programming Tools in Pharmaceutical Research
Morphea and Related Disorders
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Stem Cells in Clinical Application and Productization
Marine Biopharmaceuticals: Scope and Prospects
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Article Metrics
34
8
1
1